Microchips for in vitro diagnostics
DiagnoSwiss and bioMerieux have signed an exclusive licence agreement for the development and use of DiagnoSwiss electrochemical microchips in human in vitro diagnostics.
The agreement is restricted to the commercialisation and use of DiagnoSwiss' technology in immunoassays and biochemical testing, and is accompanied by a collaboration contract to jointly develop these microsystems into a new generation of analytical platform for clinical applications.
DiagnoSwiss' microchips reduce sample and reagent consumption and provide results in a very short time compared to conventional methods. Under the terms of the agreement, these microchips are developed for immunoassays and biochemical tests that are the most widely used classes of analyses performed in clinical diagnostics. They provide an essential aid to the physician for the diagnosis and monitoring of infectious diseases and numerous pathologies such as cancers, cardiovascular diseases or infections caused by an external microorganism (bacterium, virus or parasite) such as HIV or hepatitis virus.
Biofortified rice to combat vitamin B1 deficiency
New research has focused on improving vitamin B1 content in the endosperm of rice — the...
Higher levels of CO2 increase lifespan of airborne SARS-CoV-2
Carbon dioxide is a major factor in prolonging the life of SARS-CoV-2 variants present in tiny...
Energy-friendly ammonia production for fertilisers and fuel
To help reduce ammonia's energy footprint, researchers set out to create a reaction that can...
